Advanced Search
Contact | Corporate | Help

Study of Ganciclovir/Valganciclovir for Prevention of Cytomegalovirus Reactivation in Acute Injury of the Lung

Sponsors:
  • Fred Hutchinson Cancer Research Center
  • National Heart, Lung, and Blood Institute (NHLBI)
  • Genentech
Phases:
  • Phase II
IndicationsAcronym:
GRAIL
  • Acute Lung Injury
  • Acute Respiratory Distress Syndrome
Age Groups:
  • Adult
  • Senior
Gender:
Both
Names:
  • Drug: IV Ganciclovir and Valganciclovir
  • Drug: Placebo
Enrollment:
160

Additional information about NCT01335932.


SourceSolution © 2008-2012